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HCCAbstract Aim of work: To evaluate the effectiveness of transarterial chemoembolization (TACE)
combined with radiofrequency ablation (RFA) in treatment of malignant hepatic focal lesions
versus use of either TACE or RFA alone.
Material and methods: The study included 57 patients; 53 with hepatocellular carcinoma (HCC), 3
with hepatic metastases, and one case with cholangiocarcinoma.
They were divided into three groups according to the technique of treatment: the ﬁrst group (25
patients) was treated by RF alone, the second group (17 patients) was treated by TACE alone
and the third group (15 patients) was treated by combined RFA and TACE.
Results: In cases treated with RF only there was good response in 20% of hypervascular tumors and
28% of hypovascular tumors. In cases treated with TACE there was 47.06% good response in hyper-
vascular tumors and 11.76% in hypovascular tumors. While in combined use of TACE and RF there
was 60% good response in hypervascular tumors, and 26.66% in hypovascular tumors.
Conclusion: Combined interventional therapies are superior to any single therapy in treatment of
either hypervascular or hypovascular hepatic malignant tumors.
 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Radiology and Nuclear
Medicine. Open access under CC BY-NC-ND license.1. Introduction
Primary and metastatic hepatic malignancies are leading causes
of cancer death. Hepatocellular carcinoma (HCC) is one of the
most commonmalignancies in the world, responsible for an esti-
mated onemillion deaths annually. Liver resection or transplan-
tation is considered as potentially curative treatments.However,
themajority of cases are not candidates for these lines of therapy
due to many factors such as multicentric tumors, extra hepatic
metastases, early vascular invasion and poor hepatocellular
reserve due to associated cirrhosis. Recently, over the last two
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proved dramatically by using cross sectional imaging that can
detect even small lesions and replaced more invasive procedures
as angiography, exploratory laparotomy and percutaneous
biopsy. New hardware and software technology was introduced
to improve CT and MRI sensitivity of both modalities (1).
Regional interventional therapies have led to a major break-
through in the management of HCC, which include transarteri-
al chemoembolization (TACE), percutaneous ethanol injection
(PEI), radiofrequency ablation (RAF), and laser-induced ther-
motherapy (LITT). As a result of the technical development of
loco-regional approaches for HCC during the recent decades,
the range of combined interventional therapies has been contin-
uously extended. Combined RFA and TACE can theoretically
overcome the limitations of each when used alone. As the size
of the tumor increased, particularly if it exceeds 3.5 cm, the efﬁ-
cacy of RFA is generally reduced, this is likely due to the
incomplete ablation and increased blood ﬂow in larger lesions
resulting in heat loss (2).
Combined therapies for HCC, radiofrequency ablation
(RFA) and hepatic transartery chemoembolization (TACE)
prove to have clinical application either for local tumor de-
struction or to control tumor progress and recurrence rate,
however different criteria have been put forward for the differ-
ent techniques such as the type of enhancement of the tumor as
depicted by arterial phase of spiral CT which was considered as
an important factor in identifying the proper line of therapy,
whether one procedure would probably be more successful than
the other or if a combined line of therapy should be used (3).
1.1. Aim of the work
The aim of the present study is to evaluate the effectiveness of
combined therapy of radiofrequency ablation and transarterial
chemoembolization in treatment of hepatic malignancy lesions
versus use of either TACE or RFA alone.
2. Patients and methods
This study was carried out in a cancer institute hospital over a
period of three years in accordance with the guidelines of the lo-
cal ethics committee. Written informed consent was obtained
from all patients. 57 patients were included in this study; 53 with
HCC, 3 with hepatic metastases, and one case with cholangio-
carcinoma. 39 cases were males and 18 were females, their ages
ranged from 38 to 73 years. Most of the patients were cirrhotic.
The patients were divided into 3 groups:
 The ﬁrst group: included 25 patients with multiple
tumors not more than 3 in numbers, size of the lesions
not more than 3 cm and impaired liver functions, to
whom only RFA was done (one to two sessions).
 The second group: included 17 patients with large sized
tumors, hypervascular tumors, multifocal hepatocellu-
lar carcinomas and no portal vein thrombosis is present,
to whom only TACE: was done (one to two sessions).
 The third group: included 15 patients with small to
intermediate sized tumors, multiple foci and tumors
with indistinct boundary, to whom transarterial
chemo-embolization was done followed by radiofre-
quency ablation (RF) within 3 days.All the patients were subjected to:
Laboratory studies: complete blood count, platelet count,
prothrombin time and liver tumor marker mainly alpha-feto-
protein (AFP).
(1) Abdominal ultrasound and Doppler study for the liver,
to detect the size, echo pattern and number of focal
lesions, and to assess the portal vein and its branches
to exclude thrombosis.
(2) Multiphasic computed tomography, to examine the liver
on arterial phase 22–25 s, portal phase 70–90 s and
delayed phase 5–10 min after the start of bolus injection
of 100 ml of Ultravist using power injector (rate 3 ml/s).
Slice thickness: 7 mm.
(3) Radiofrequency ablation was done under CT guidance
for localization of the tumor and accurate insertion of
the electrode. We use the cool tips RF systems.
2.1. RF procedure
Number of RF sessions was 1–3 sessions.
 At the site of needle puncture, local anesthesia was
injected to all patients and small skin incision was
made.
 Each application of RF energy lasted for 14 min; the
entire treatment session was about one hour.
 Grounding was achieved by attaching 2 dispersive pads
to patient’s thighs.
 A peristaltic pump was used to infuse normal saline
(0 C) into lumen of the electrodes to maintain a tip
temperature to 20–25 C.
(1) Hepatic arterial embolization:
- Selective hepatic angiography through Transfemoral
Seldinger Technique was conducted with a digital
angiographic unit.
Patients were injected by a mixture of lipidol and cytotoxic
drugs, through the catheter into the tumor vascular bed under
screen, until the lipidol was densely accumulated into the tu-
mor, this is followed by occlusion of the tumor vascular bed
by gel foam particles before RF ablation.
(1) Most of the patients (53 patients) were referred to sub-
ject biopsy to conﬁrm the diagnosis.
2.2. Data analysis
The patients were classiﬁed according to the arterial phase of
spiral CT which was reviewed before treatment into: type I
pattern = predominantly hypervascular lesions (>90% of
the lesion enhances more than the adjacent liver parenchyma)
and type II pattern = predominantly hypovascular lesions
(less than 50% of the lesion enhances more than the adjacent
liver parenchyma).
The response was evaluated by multiphasic CT and alpha
fetoprotein. Multiphasic CT: the response was considered
complete when CT scan showed the total disappearance of
enhancement within the neoplastic tissue (the lesion showed
Table 2 Response after TACE only (group II).
Group II Type 1 Type 2 Total
Good response 8 2 10
47.06% 11.76%
Poor response 2 5 7
11.76% 29.41%
Total 10 7 17
Table 3 Response after combined therapy TACE + RFA.
Group III Type 1 Type 2 Total
Good response 9 4 13
60% 26.66%
Poor response 1 1 2
6.67% 6.67%
Total 10 5 15
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lesion.
3. Results
AFP level in all patients was above 100 ng/ml before treat-
ment, which showed marked decrease in level after treatment.
 In cases treated with RF only, there was signiﬁcant dif-
ference regarding response after RFA treatment in type
II patients as compared with response in type I. There
was 16 patients of type I enhancement, 5 (20%) of them
showed good response and 11 (44%) showed poor
response. The other 9 patients were of type II enhance-
ment, 7 (28%) of them showed good response and 2
(8%) showed poor response (Table 1).
 There was signiﬁcant difference regarding response
after RFA treatment in type II patients as compared
with response in type I. As regards the level of AFP,
there were much decreased levels of AFP in type II
compared with type I (pre 300–450 ng/ml and post-
treatment 20–30 ng/ml in type II).
 In 17 cases treated with TACE only, there was signiﬁ-
cant difference regarding response after TACE treat-
ment in type I enhancement as compared with in type
II. Hypervascular enhancement type I was in 10 cases;
8 (47%) patients showed good response and 2 (11.8%)
patients showed poor response. Hypovascular pattern,
type II was in 7 cases; 2 (11.7%) showed good response
and 5 (29%) showed poor response (Table 2).
 There were much decreased levels of AFP in type I
compared with type II (pre 320–900 ng/ml and post-
treatment 30 ng/ml in type I).
While in the remaining 15 cases treated with combined ther-
apy TACE + RFA there was hypervascular enhancement
(type I) in 10 patients, 9 (60%) cases showed good response
and 1 (6.7%) case showed poor response while in the 5 cases
with hypovascular pattern there was good response in 4
(26.7%) of them and poor response in 1 (6.7%) case (Table 3).
Combined interventional therapy was superior to any single
therapy in treatment of hepatic malignancies of both type I
and type II enhancement.
Regarding comparison between levels of AFP pre and post
treatment, there was highly signiﬁcance difference in AFP level
in patients treated by the combined therapy. AFP levels pre
and post treatment were 949.26 and 306.72, respectively.
Regarding CT ﬁndings, there was a signiﬁcant tumor necro-
sis and disappearance of enhancement within the neoplastic
tissue in combined therapy.Table 1 Response after RF only (group I).
Group I Type 1 Type 2 Total
Good response 5 7 12
20% 28%
Poor response 11 2 13
44% 8%
Total 16 9 254. Discussion
There are several interventional techniques aiming to provide
local destruction of tumors have been developed and clinically
tested over the past few years. Among these procedures are
RFA, TACE or combination between each (4).
In our study we categorized the patients into three groups
according to the technique done for each group of patients.
Group I (25 patients) underwent RFA alone, group II (17
patients) underwent TACE alone and group III (15 patients)
underwent combined TACE + RFA therapy. The vascularity
of the tumor as depicted by the arterial phase of multiphasic
CT was analyzed as an important factor to identify the pattern
of tumor enhancement to plane the proper line of therapy.
HCC has a variety of appearances on CT, the typical
appearance is lesion that is less dense than the adjacent liver
on unenhanced CT and that shows hypervascular enhance-
ment during the hepatic arterial phase, in other, the lesions
appeared as hypovascular lesion on contrast CT images (5).
Radiofrequency ablation is a widely accepted minimally
invasive treatment option for selective patients because of its
efﬁcacy, safety, easiness and can be performed in an outpatient
basis (6).
The postablation imaging is a critical component of the
procedure not only for the interventionalist who perform
the procedure but also for the diagnostician who interprets
the postablation imaging to differentiate normal from abnor-
mal post-ablation imaging ﬁndings to prevent overcalling
benign changes as abnormal and can thus avoid needless
treatment (7).
In our study, group I included (25 patients) to whom only
radiofrequency ablation was done. These patients are sub
grouped according to arterial phase multiphasic CT images
before the procedure into, patients with type I enhancement
‘‘hypervascular lesions’’ and patients with type II enhancement
‘‘hypovascular lesions.’’ It was noted that hypovascular
tumors (type II) showed a signiﬁcantly success rate with
RFA than hypervascular tumors (type I), denoting that
increased vascularity is an important factor in hindering the
process of ablation. Our results showed 28% good response
in type II and 20% in type I, and 2% poor response in type
II in comparison to 44% poor response in type I (Fig. 1).
(a) (b)
Fig. 1 71-year-old female patient with focal liver lesion at the posterior segment of right lobe, biopsy proved HCC, showing faint
enhancement in the arterial phase type II enhancement (a), treated with two sessions of RFA. Follow up multiphasic CT after one month
revealed complete ablation of the lesion (b).
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quency ablation induces in situ thermal coagulation necrosis
through the delivery of high frequency alternating current to
the tissue. Multiphasic CT is used to determine whether the
ablation has been completed and to screen for early recur-
rences that may beneﬁt from reablation. Complete ablation
creates an area of necrosis that, at CT, is of low attenuation
compared with the surrounding liver tissue (8).
In a contrast enhancement CT, when the ablation zone is
well demarcated with no enhancement seen this suggests a lack
of viable tumor and so indicates that the treatment was
adequate (9).
In our study we use multiphasic CT to discriminate ablated
from residual viable tumor in the hepatic arterial phase imag-
ing, which showed a region of hypoattenuation devoid of char-
acteristic tumor or tissues enhancement where enhanced tissue
within the hypoattenuated ablated area indicates residual tu-
mor. It was also noted that images during arterial phase may
also show a thin rim of contrast material corresponding to
an early inﬂammatory reaction to the thermal damage. These
inﬂammatory changes can be seen immediately after ablation
and often regress during the ﬁrst month after treatment and
should not be misinterpreted as residual tumor.
Treatment by RF of low vascular tumors as shown by the
low contrast enhancement in CT scans, shows a higher success
rate whereas highly vascular lesions are difﬁcult to treat with
rapid progression and post treatment regrowth (10).
In our study, tumor of pattern II enhancement showed a
signiﬁcantly higher success rate to RFA than those of type I
enhancement, denoting that increased vascularity is an impor-
tant factor in hindering the process of ablation.
Indication of RFA should be candidates based on impaired
liver function or can be used as bridge therapy for patients
awaiting transplantation or with multiple tumors (not more
than three in number and <3 cm in size). He also stated that,
potential candidates for RFA include patients with inoperable
tumors that cannot be chemoembolized due to severe liver dys-
function or hypovascularity and patients with tumors that
failed chemoembolization. The main advantage of RFA is
the ability to create coagulation necrosis by heat regardless
of the presence of ﬁbrous tissue or septa (11).
Many complications for RFA include recurrent or residual
tumors, tumor seedling along tracks of ablation electrodes.Biliary or vascular complications although rare could occur.
Mild to moderate pain during the procedure and for one to
two days after the procedure, hyperpyrexia for several days
following treatment as a result of necrotic phenomena, skin
burn at the site of needle introduction and rarely abscess
formation could occur (10).
In our study, no major complications were recorded. But
the majority of patients had mild to moderate pain which
needed only sedation.
4.1. Group II
Included (17 patients) to whom transarterial chemoemboliza-
tion was done, and these patients were sub grouped according
to multiphasic CT results before the procedure into, patients
with type I enhancement ‘‘hypervascular lesions’’ and patients
with type II enhancement ‘‘hypovascular lesions’’ (Fig. 2).
Transarterial chemoembolization is an effective treatment
not only for multifocal HCCs, but also for large monofocal
and inﬁltrative HCCs, where the liver is a particularly favor-
able organ for arterial supply of portal vein alone, where por-
tal vein supplies 70% of the blood reaching the liver (12).
TACE takes the advantages of the fact that most HCC is
very vascular tumor, gets its blood supply exclusively from
branches of the hepatic artery, in contrast to systemic chemo-
therapy, this procedure has additional steps of blocking
(embolizing) the small vessels by gel foam, causing exposure
of the tumor to high concentration of chemotherapy and con-
ﬁning the agents locally since they are not carried away by
blood stream. In addition this technique deprives the tumor
from its needed blood vessels and so tumor shrinks up to
70%, the new trend in TACE is blockage of blood vessels by
microscopic drug-eluting beeds which is more effective (13).
TACE is the combination of TAE and regional chemother-
apy, this combination has synergistic anti-tumor effect with
high objective response rate and with a lower systemic drug
level, therefore has less toxicity. There are different embolic
agents, and it is important to choose the most appropriate
agent according to tumor size and tumor vascularity. The
potential therapeutic effects are considered to be a function
of micro infarction and prolonged drug release. The desirable
feature of such a modality is the lessened systemic toxicity of
the chemotherapy and simultaneous necrotic effect on the
(a) (b)
Fig. 2 59-year-old male patient with a large well deﬁned hepatic focal lesion in the posterior segment of right lobe (proved by biopsy to
be HCC), with type 1 enhancement at multiphasic CT (a). The patient was treated by TACE. Follow up after ﬁve weeks, revealed good
response with dense lipidol concentration in the lesion (b).
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and increase the contact time of the chemotherapeutic agent
with the neoplasm and increase the tissue permeability because
of the anoxia (14).
TACE technique is rarely a cure for malignant liver cancer,
their studies had shown that 20–70% cancer shrinks in size
compared with untreated cases, it may relieve pain and other
signs and symptoms, make patients more comfortable, but it
has some limitations: it cannot be done to all patients as it
necessitates good general condition, reasonable liver condition,
absence of portal vein thrombosis , albumin >3.5 gm/dl, and
has its own complications which are: liver abscess , septicemia
, deteriorated liver function and Gall bladder or splenic infarc-
tion. 60–70% patients treated by TACE die due to tumor pro-
gression during follow up or due to eventual regrowth of the
residual tumor cells after regaining a vascular supply or due
to disease complications (15).
No major complications occurred in our work except post
embolization syndrome: fever, nausea, vomiting and abdomi-
nal pain, which resolved spontaneously.
The response of our study was evaluated by multiphasic
CT, signiﬁcant response to TACE was more in type I enhance-
ment tumors, 47% showed good response in type I with only
11% with type II this, ﬁnding was also conﬁrmed by (10).(a) (b)
Fig. 3 66-year-old patient had liver cirrhosis with focal of HCC in th
was of type 1 enhancement (a). Selective hepatic angiogram revealed
therapy (tumor embolization followed by one RF session). Follow
embolization of the feeding artery (c–d).4.2. Group III
Included (15 patients) to whom combined transcatheter hepa-
tic arterial chemoembolization was done followed by radio fre-
quency ablation. RFA combined with chemoembolization has
a therapeutic effect on small and intermediate size HCCs
regardless of tumor morphology and is a promising treatment
option for large nodular lesions (16). CT criterion is disappear-
ance of enhancement within the neoplastic tissue due to tumor
necrosis.
The combination of radiofrequency ablation and transcath-
eter arterial chemoembolization markedly increased the extent
of induced coagulation compared with radiofrequency alone.
He found that local response of RFA alone and in combina-
tion with TACE was 17.3% and 70%, respectively, recurrence
rate in RFA alone and in combination with TACE was 20%
and 6.7%, respectively (17).
In our study combination therapy was done for (15
patients) and the theraputic response was evaluated by
multiphasic CT (arterial phase) and alpha-feto-protein level,
patients showed good response in hypervascular type 1
enhancement (60%) and 26% in the hypovascular type 11
enhancement and patients who were treated with combined
therapy showed a signiﬁcantly higher success rate as compared(c) (d)
e right lobe of liver, in arterial phase of multiphasic CT, the lesion
vascularity of the mass (b). The patient was treated by combined
ed up after three weeks, CT revealed complete ablation with
122 G.H. Gamal et al.with patients who treated by RFA only or TACE only (Fig. 3).
These results were completely in agreement with what was con-
cluded by many authors (5,9).
Zhu and Salem (2), reported that for those hepatocellular
carcinoma over 3 cm in size, located in the porta hepatis, or
with indistinct boundary or the presence of multiple foci,
TACE can be performed ﬁrst and then followed by RFA in
suitable time this might reduce or eliminate the heat loss that
is mediated by tissue perfusion to enlarge the necrosis range
and increase the rate of complete necrosis of tumors, thereby
decrease the recurrence and improve the disease free survival
and total survival of patients.
Gary et al. (1) stated that new hardware and software tech-
nology was introduced to improve CT and MRI sensitivity of
both modalities in ability to detect HCC and can now replace
more invasive procedure in diagnosis as angiography, explor-
atory laparotomy and percutaneous biopsy. He also added
that, combined therapy of TACE and RFA has further advan-
tages it provided a way to highlight and treat lesions not rec-
ognizable through other imaging techniques, increased the
accumulation of lipid contrast in the tissue surrounding the le-
sion and in the vessels not occluded by thermal ablation in the
lesion and enables further treatment of tumor residue possibly
left untouched by thermal ablation in large tumors.
Our results showed also that there was highly signiﬁcant
difference in AFP level in group III than in group I or II. Upon
comparison regarding survival after one year, there was a sig-
niﬁcant difference after combination treatment in group III
than that of group I or II.
5. Conclusion
 Combined interventional therapies are superior to any
single therapy for improving the prognosis and survival
of patients with HCC.
 With the advent of new interventional techniques aim-
ing at providing local destruction of HCC, the proper
selection of appropriate therapy has become manda-
tory, and we found that patients who responded to
RFA and TACE had correlated closely with tumor vas-
cularity as shown on hepatic arterial phase multiphasic
CT.
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